Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT ID: NCT01950273

Last Updated: 2018-09-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 95 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-09-27
• Study Completion Date: 2015-12-22

Brief Summary

The primary objective of the study is to assess the pharmacokinetic (PK) similarity of Boehringer Ingelheim (BI) 695500 vs. rituximab (MabThera®) in previously untreated patients with low tumor burden follicular lymphoma (LTBFL).

The secondary objective of the study is to evaluate the pharmacodynamics (PD), safety, and anti-tumor activity of BI 695500 vs. rituximab (MabThera®), as well as the presence of anti-drug antibodies (ADAs).

Conditions

Lymphoma, Follicular

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

BI695500

BI695500, once a week for 4 weeks (4 administrations in total)

Group Type: EXPERIMENTAL

BI 695500

Intervention Type: DRUG

BI695500, once a week for 4 weeks (4 administrations in total)

MabThera

MabThera, once a week for 4 weeks (4 administration in total)

Group Type: ACTIVE_COMPARATOR

MabThera

Intervention Type: DRUG

MabThera, once a week for 4 weeks (4 administrations in total)

Interventions

BI 695500

BI695500, once a week for 4 weeks (4 administrations in total)

Intervention Type: DRUG

MabThera

MabThera, once a week for 4 weeks (4 administrations in total)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Must give written informed consent and be willing to follow this Clinical Trial Protocol.
• Male or female patients, at least 18 years of age at Screening.
• Histologically-confirmed, stage II - IV Non-Hodgkin's lymphoma (CD20+ FL of Grades 1, 2, or 3a).
• Low tumor burden according to the Groupe d'Etudes des Lymphomes Folliculaires (GELF) criteria - no nodal or extranodal involvement of more than 7 cm, no more than 3 nodal sites with a diameter >3 cm, no B symptoms (i.e., fever >38°C, weight loss - unexplained loss of >10 % body weight over the past 6 months, and sweats - the presence of drenching night sweats), no significant splenomegaly, no significant serious effusion, no complications such as organ compression, and less than 5x10^9/L circulating tumor cells.
• Availability of archived tumor sample prior to screening.
• Patients not previously treated for their FL.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• Have at least 1 measurable lesion as per the International Working Group (IWG) criteria 2007 at Screening (lesion clearly measurable in at least 2 perpendicular dimensions; see Appendix 10.1 for further details).
• Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow) within 28 days prior to randomization, including:
• - hemoglobin =9.0 g/dL (=5.6 mmol/L).
• - absolute neutrophil count =1.5 × 10^9/L.
• - platelet count =100 × 10^9/L.
• Adequate renal and liver function:
• - serum creatinine <2.0 mg/dL (<176.8 micromol/L).
• - total bilirubin <2.0 mg/dL (<34 mcmol/L) except for patient with Gilbert's Syndrome or Hemolysis. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 x upper limit of normal (ULN) (<5 x ULN is acceptable if abnormalities are thought to be related to hepatic infiltration by FL).
• For participants of reproductive potential (males and females), use of a medically acceptable method of contraception during the trial, i.e., a combination of 2 forms of effective contraception (defined as hormonal contraception, intrauterine device, condom with spermicide, etc.). Females of childbearing potential (includes tubal ligation) and males with female partners of childbearing potential must also agree to use an acceptable method of contraception (see above) for 12 months following completion or discontinuation from the trial medication.

Exclusion Criteria

• Transformation to high-grade lymphoma (secondary to low-grade lymphoma).
• Presence or history of central nervous system lymphoma.
• Patients receiving current treatment with corticosteroids must not be receiving a dose exceeding 20 mg/day prednisone or equivalent.
• Patients with prior or concomitant malignancies within 5 years prior to screening except non-melanoma skin cancer, adequately treated carcinoma in situ of the cervix, adequately treated breast cancer in situ, localized prostate cancer stage T1c - provided that the patient underwent curative treatment, and remains relapse free.
• Major surgery (excluding lymph node biopsy) within 28 days prior to randomization.
• Active, chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., Human Immunodeficiency Virus [HIV], Hepatitis C Virus [HCV], Herpes Zoster); positive for HIV or tuberculosis at Screening.
• Patients with serological evidence of Hepatitis B virus (HBV) infection. Patients seropositive because of HBV vaccine are eligible. HBV positive patients may participate following consultation with a hepatitis expert regarding monitoring and use of HBV antiviral therapy, and provided they agree to receive treatment as indicated.
• Serious underlying medical conditions, which, per the investigator's discretion, could impair the ability of the patient to participate in the trial (including but not limited to ongoing active infection, severe immunosuppression, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease); patients who have significant cardiac disease, including but not limited to congestive heart failure of Class III or IV of the NYHA classification; uncontrolled angina or arrhythmia; any uncontrolled or severe cardiovascular or cerebrovascular disease.
• Known hypersensitivity or allergy to murine products.
• History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug.
• Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit.
• Prior treatment with BI 695500 and/or rituximab.
• Patients who received any prior therapy using monoclonal antibodies will be excluded; this does not apply to other biological drugs such as growth factors or anticoagulants.
• Treatment within a clinical trial within 4 weeks prior to initiation of trial treatment. Patients who have received treatment with a drug that has not received regulatory approval for any indication within 4 weeks or a minimum of 5 half-lives, whichever is longer, of the initial dose of trial medication.
• Any other co-existing medical or psychological condition(s) that will preclude participation in the trial or compromise ability to give informed consent and/or comply with study procedures.
• Pregnancy or breast feeding. For women of childbearing potential, a positive serum pregnancy test at the Screening Visit.
• Patients who have significant cardiac disease, including but not limited to congestive heart failure of Class III or IV of the New York Heart Association (NYHA) classification; uncontrolled angina or arrhythmia; any uncontrolled or severe cardiovascular or cerebrovascular disease; or uncontrolled hypertension.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

The Canberra Hospital

Canberra, Migration Data, Australia

AKH - Medical University of Vienna

Vienna, , Austria

Brussels - UNIV St-Luc

Brussels, , Belgium

UZ Leuven

Leuven, , Belgium

Namur - HOSP Ste-Elisabeth

Namur, , Belgium

Clinical Hospital Centre Zagreb

Zagreb, , Croatia

University Hospital Brno

Brno, , Czechia

University Hospital Ostrava

Ostrava-Poruba, , Czechia

Vseobecna fakultni nemocnice V Praze

Prague, , Czechia

INS Bergonié

Bordeaux, , France

HOP Morvan

Brest, , France

Centre Hospitalier Départemental Les Oudairies

La Roche-sur-Yon, , France

HOP Haut-Lévêque

Pessac, , France

Hôpital la Milétrie - CHU Poitiers

Poitiers, , France

Gesundheitszentrum Wetterau gGmbH

Bad Nauheim, , Germany

Universitätsklinikum Carl Gustav Carus Dresden

Dresden, , Germany

Universitätsklinikum Freiburg

Freiburg im Breisgau, , Germany

Haemato-Onkologie Hamburg

Hamburg, , Germany

Klinikum Kassel GmbH

Kassel, , Germany

General Hospital of Athens "G. Gennimatas"

Athens, , Greece

Semmelweis University, 1st Dept. Internal Medicine

Budapest, , Hungary

Auckland Clinical Studies Ltd

Auckland, , New Zealand

Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer

Warsaw, , Poland

BHI of Omsk region - Clinical Oncology Dispensary

Omsk, , Russia

St. Petersburg GUZ City Clinical Oncology Dispensary

Saint Petersburg, , Russia

Hospital Germans Trias i Pujol

Badalona, , Spain

Hospital Puerta del Mar

Cadiz, , Spain

Fundación Jiménez Díaz

Madrid, , Spain

Hospital Virgen del Rocío

Seville, , Spain

Countries

Australia; Austria; Belgium; Croatia; Czechia; France; Germany; Greece; Hungary; New Zealand; Poland; Russia; Spain

Other Identifiers

2013-001904-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1301.5

Identifier Type: -

Identifier Source: org_study_id